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Introduction
Malignant Hyperthermia (MH)
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Malignant Hyperthermia is a rare
hypermetabolic condition (Cornelius et
al., 2019).
MH is a disorder of the skeletal muscle
(Lapisatepun & Arkarattanakul, 2020).
It is caused by a genetic mutation of
ryanodine receptor proteins in skeletal
muscle cells (Cornelius et al., 2019).
MH is caused by inhaled anesthetics
and the paralytic medicated
succinylcholine (Gallegos & Hennen,
2022).
The first case in the United States was
reported in 1922 (Cornelius et al.,
2019).
MH was fully described in 1951
(Cornelius et al., 2019).
MH effects 1/100,000 patients
undergoing surgery in an inpatient
setting (Cornelius et al., 2019).
It effects 1/500,000 patients
undergoing surgery in outpatient
settings (Cornelius et al., 2019).
1/15,000 pediatric surgical patients
are diagnosed with MH (Lapisatepun &
Arkarattanakul, 2020).

Signs and Symptoms
The initial symptoms are often
unexplained (Hopkins et al., 2021).
MH can cause:
•
Jaw stiffness
•
Limb rigidity
•
Hyperthermia
•
Tachycardia
•
Hypercarbia
•
Flushed skin (Hopkins et al., 2021)
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MH historically had a fatality rate of
70% (Gallegos & Hennen, 2022).
The fatality rate is now 5% when
appropriate treatment is given
quickly (Cornelius et al., 2019).
While there are treatments that can
significantly improve outcomes,
anesthesia providers must be able to
quickly recognize the condition in
order to begin treatment (Gallegos &
Hennen, 2022).
Without recognition, emergency
medications likely cannot be given
fast enough.
The faster the medications are given,
the higher the survival chance is
(Gallegos & Hennen, 2022).
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MH can lead to deadly conditions such
as:
•
Hyperkalemia
•
Rhabdomyolysis
•
Disseminated intravascular
coagulopathy (DIC)
•
Acidosis (Hopkins et al., 2021)
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MH is caused by certain types of anesthesia medications, such as sevoflurane, isoflurane, desflurane, and succinylcholine (Cornelius
et al., 2019)
In normal muscle physiology, action potentials move down T-tubules and open channels by stimulating dihydropyridine receptors
Dihydropyridine receptors then open ryanodine receptor proteins.
When these proteins open, calcium that is stored in the sarcoplasmic reticulum is released.
The calcium quickly binds to a troponin complex, which causes actin to bind to myosin, causing muscle contraction.
The ryanodine receptor protein is inhibited by magnesium, stopping the outflow of calcium, stopping the muscle contraction
(Cornelius et al., 2019).
In Malignant Hyperthermia, there is a mutation in the ryanodine receptor proteins.
This mutation causes the proteins to block the magnesium, preventing inhibition of the receptor.
Because the receptor is not inhibited, too much calcium is released from the sarcoplasmic reticulum.
With too much calcium flowing out and binding to troponin complexes, muscles are contracted for too long and cannot relax.
This causes too much ATP to be used during the muscle contraction (Cornelius et al., 2019).

tubule

To keep muscle cells alive during the extended contractions, more ATP must be produced and used.
This causes increased metabolism, creating the ”hypermetabolic” condition.
The increased utilization of ATP causes increased CO2, which causes acidosis and tachypnea (Cornelius et al., 2019).
The increased metabolism also creates heat, causing hyperthermia and flushed skin (Cornelius et al., 2019).
The hyperkalemia caused by hypermetabolism can cause deadly cardiac dysrhythmias (Hopkins et al., 2021).
The pathophysiology of MH can be extremely dangerous and must be treated as fast as possible (Kleidon, 2020).
MH can cause hemodynamic instability, dysrhythmias, and death (Gallegos & Hennen, 2022).
It can also cause rhabdomyolysis (Otta et al., 2021).
MH can lead to kidney injury (Tsutsumi et al., 2021).
After treatment, patients go to the Intensive Care Unit for further monitoring and treatment (Kleidon, 2020).
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MH is difficult to diagnose, so the Larach
Clinical Grading Scale is used to score patients
based on symptoms to determine likelihood of
MH (Cornelius et al., 2019).
•
Once MH is recognized in the operating room,
the medication that caused it must be stopped
immediately.
•
The treatment for MH is Dantrolene Sodium.
Dantrolene blocks the effects of
dihydropyridine receptors, decreasing the
release of sodium.
•
This stops the contractions that cause the
hypermetabolic state (Lapisatepun &
Arkarattanakul, 2020).
•
The treatment starts with 2.5mg/kg of
Dantrolene and then increased until symptoms
stop.
•
The maximum dose of Dantrolene is 10mg/kg
(Cornelius et al., 2019).
After the initial MH treatment is given to prevent
further damage, the effects of MH must be treated.
These include:
•
Sodium bicarbonate for acidosis
•
IV calcium and glucose/insulin for
hyperkalemia
•
Amiodarone for dysrhythmias
•
Sodium bicarbonate for myoglobinuria
•
Coagulation transfusions for DIC (Hopkins et
al., 2021)
•

Implications for
Nursing Care
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Figure 1: “Pathomechanisms and therapeutic approach in malignant hyperthermia” (Malignant Hyperthermia, 2021, p. 1)

Conclusion

Treatment

Significance of Pathophysiology

Due to the specific combination of
symptoms that can mimic other
problems, other conditions must be
quickly ruled out. Other conditions that
look similar to MH that should be ruled
out include:
•
Anaphylaxis
•
Neuroleptic malignant syndrome
(NMS)
•
Sepsis
•
Serotonin syndrome (Cornelius et
al., 2019)

Significance
•

Underlying Pathophysiology
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Malignant Hyperthermia is
hypermetabolic condition that
occurs after some patients
receive certain anesthetic
medications during surgery
(Kleidon, 2020).
MH is an extremely dangerous
condition that everyone at a
surgical facility needs to be
aware of.
Having a plan in place to treat
MH is essential to preventing
death caused by the condition.
In order to prevent MH deaths
anesthesia providers must
understand the pathophysiology
behind it and how to treat it.
The death rate from MH has
decreased dramatically but only
if treatment is given quickly
(Cornelius et al., 2019).
All providers must remain
vigilant of the disease even
thought it is very rare (Cornelius,
et al., 2019).
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Because of the detrimental effects of MH,
nurse anesthetists must always be aware of
the possibility of MH, even though it is
extremely rare (Cornelius et al., 2019).
It is treatable when caught early, so nurse
anesthetists must recognize the condition
quickly (Cornelius et al., 2019).
Understanding the pathophysiology is vital
to recognize the condition and treat
adequately.
Susceptible patients can be screened with a
surgical biopsy (Carlson et al., 2019).
Cognitive aids should be posted anywhere
that anesthesia is administered to shorten
treatment time (Gallegos & Hennen, 2022).
There should also be MH emergency kits
anywhere that anesthesia is administered
containing treatment medications and
devices (Gallegos & Hennen, 2022).
Dantrolene should be available to
administer within 10 minutes (Lapisatepun
& Arkarattanakul, 2020).
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